Liver fibrosis is associated with cutaneous inflammation in the imiquimod‐induced murine model of psoriasiform dermatitis. (1st July 2018)

• Record Type: Journal Article
• Authors: Vasseur, P.; Pohin, M.; Jégou, J.F.; Favot, L.; Venisse, N.; Mcheik, J.; Morel, F.; Lecron, J.C.; Silvain, C.
• Is Part Of: British journal of dermatology. Volume 179:Number 1(2018)
• Page Start: 101
• Page End: 109
• Publication Date: 2018-07-01
• Subjects: Dermatology -- Periodicals; Skin -- Diseases -- Periodicals; 616.5
• DOI: 10.1111/bjd.16137
• Languages: English
• ISSNs: 0007-0963

Abstract

Summary: Background: Psoriasis exhibits several extracutaneous manifestations. Little is known about hepatic parameters specifically associated with psoriasis. Objectives: To study whether psoriasiform dermatitis is associated with liver injury. Methods: We studied liver parameters of inflammation and fibrosis in a murine model of psoriasiform dermatitis induced by topical application of imiquimod for 9 weeks. Results: Topical treatment with imiquimod induced a form of psoriasiform dermatitis reminiscent of the human disorder, characterized by thickened and scaly skin, psoriasiform epidermal hyperplasia, altered keratinocyte differentiation and cutaneous overexpression of interleukin‐17A. Mice with dermatitis displayed hepatitis, as shown by elevation of plasma transaminase levels, as well as portal and periportal hepatitis, characterized by T‐lymphocyte (CD3ε + ) and polymorphonuclear cell (Gr1 + ) infiltrates. The hepatitis progressed towards liver fibrogenesis, as shown by excessive Sirius red staining, which is consistent with the expression of α‐smooth muscle actin by hepatic stellate cells. Conclusions: These results indicate that liver inflammation and fibrosis are associated with experimental psoriasiform dermatitis. Our results suggest that psoriatic inflammation may be associated with specific liver injury.